Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 15/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846363 | 1.00 | DNM1 (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL848237 | 0.88 | DNM1 (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL848238 | 0.88 | DNM1 (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL30772486 | 0.86 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL846753 | 0.86 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL846754 | 0.86 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL29426400 | 0.86 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL6213506 | 0.83 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL6213511 | 0.83 | EGFR (1.00) | DNM1EGFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL846328 | 0.82 | DNM1 (0.72) | DNM1EGFRKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115175-A1 | NICORANDIL DERIVATIVES | UNICYCIVE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3937938-B1 | NICORANDIL DERIVATIVES | UNICYCIVE THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250341512-A1 | HIGH-THROUGHPUT AUTOMATION OF ORGANOIDS FOR IDENTIFYING THERAPEUTIC STRATEGIES | UNIVERSITY OF WASHINGTON (US) | 2025-11-06 | — | — | US | disclosed |
| US-12396989-B2 | Nicorandil derivatives | UNICYCIVE THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12377082-B2 | Nicorandil derivatives | Unicycive Therapeutics Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12320800-B2 | High-throughput automation of organoids for identifying therapeutic strategies | UNIVERSITY OF WASHINGTON (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250145571-A1 | AMINO ACID PRODRUGS OF NICORANDIL | UNICYCIVE THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025072556-A1 | AMINO ACID PRODRUGS OF NICORANDIL | UNICYCIVE THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-2911692-B1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | UNIV QUEENSLAND (AU) | 2019-08-21 | — | — | EP | disclosed |
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-04-09 | — | — | US | disclosed |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-10-08 | — | — | US | disclosed |
| EP-2911692-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | The University of Queensland (AU) | 2015-09-02 | — | — | EP | disclosed |
| EP-2432465-B1 | USE OF DYNAMIN RING STABILIZERS | CHILDREN S MEDICAL RES INST (AU) | 2015-07-22 | — | — | EP | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| WO-2014063205-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-05-01 | — | — | WO | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432465-A1 | USE OF DYNAMIN RING STABILIZERS | Children's Medical Research Institute (AU) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010132959-A1 | USE OF DYNAMIN RING STABILIZERS | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377082-B2 | Nicorandil derivatives | NAPRT, NQO1, NME4 | DNM1 2341/4885EGFR 1713/4885KDM4E 4061/4885 |
| US-20250145571-A1 | AMINO ACID PRODRUGS OF NICORANDIL | NAPRT, SLC1A5, ASNS | DNM1 3313/4885EGFR 1008/4885KDM4E 3752/4885 |
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | CLINT1, CLTC, DNM1L | DNM1 4/4885EGFR 12/4885KDM4E 2577/4885 |
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | DNM1 1/4885EGFR 1355/4885KDM4E 2562/4885 |
| US-20260115175-A1 | NICORANDIL DERIVATIVES | XDH, MT-ND4L, NNT | DNM1 1945/4885EGFR 1908/4885KDM4E 3625/4885 |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | CLINT1, CLTC, DNM1L | DNM1 4/4885EGFR 12/4885KDM4E 2577/4885 |
| US-12396989-B2 | Nicorandil derivatives | NAPRT, NQO1, NME4 | DNM1 2341/4885EGFR 1713/4885KDM4E 4061/4885 |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | DNM1L, DNM1, DNM2 | DNM1 2/4885EGFR 3915/4885KDM4E 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.